EPZ-6438 also eliminates the growth of several EZH2 mutant xenografts including WSU-DLCL2 (Y641F), Pfeiffer (A677G), KARPAS-422 (Y641N) etc., and has been approved for human clinical trials in patients with advanced solid tumors or with B-cell lymphoma [58]. The gene discussed is EZH2; the disease is B-cell non-Hodgkin lymphoma.